Cholesterol-lowering drugs and coronary artery disease
Citations
Lewis SJ, et al. (1998). Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: Results of the Cholesterol And Recurrent Events (CARE) trial. Annals of Internal Medicine, 129(9): 681–689.
Waters DD, et al. (2002). Effects of atorvastatin on stroke in patients with unstable angina or non–Q-wave myocardial infarction. Circulation, 106(13): 1690–1695.
Gami A (2006). Secondary prevention of ischaemic cardiac events, search date July 2004. Online version of Clinical Evidence (15): 1–31.
Schwartz GG, et al. (2001). Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: A randomized controlled trial. JAMA, 285(13): 1711–1718.
Cannon CP, et al. (2004). Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine, 350(15): 1495–1504.
Nissen SE, et al. (2004). Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. JAMA, 291(9): 1071–1080.
Grundy SM, et al. (2004). Implications of recent clinical trials of the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation, 110(2): 227–239. [Erratum in Circulation, 110(6): 763.]
LaRosa JC, et al. (2005). Intensive lipid lowering with atorvastatin in patients with stable coronary artery disease. New England Journal of Medicine, 352(14):1425-1435.
| Author: | Robin Parks, MS | Last Updated: May 29, 2008 |
| Medical Review: | Caroline S. Rhoads, MD - Internal Medicine Robert A. Kloner, MD, PhD - Cardiology Ruth Schneider, MPH, RD - Diet and Nutrition | |
 | ||